Stock OMGA OMEGA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.13 USD +14.52% Intraday chart for Omega Therapeutics, Inc. +7.58% -29.24%
May. 30 Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer CI
May. 29 Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer
CI
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
GL
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
GL
Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer
CI
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
GL
Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
GL
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
GL
Omega Therapeutics CFO Joshua Reed to Depart
MT
Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024
CI
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024
CI
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
GL
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control
CI
Piper Sandler Trims Price Target on Omega Therapeutics to $9 From $10, Maintains Overweight Rating
MT
Chardan Cuts Price Target on Omega Therapeutics to $7 From $12, Keeps Buy Rating
MT
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss
MT
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
GL
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OMGA Stock
  4. News Omega Therapeutics, Inc.